Zosano Pharma Corporation (NASDAQ:ZSAN) Sellers Declined Their Shorts By 43.02%

June 29, 2018 - By Robert Judd

It was recorded a decrease on Zosano Pharma Corporation (NASDAQ:ZSAN)’s short interest with 43.02%. FINRA published short interest of ZSAN’s total 924,200 shares. That’s 43.02% down from 1.62M shares. 2 days will cost ZSAN with 523,600 average volume to recover its former position. 2.89% is Zosano Pharma Corporation float short.

ZSAN hit $4.06 during the last trading session after $0.08 change.Currently Zosano Pharma Corporation is downtrending after 85.30% change in last June 29, 2017. ZSAN has 185,578 shares volume. ZSAN underperformed by 97.87% the S&P500.

Zosano Pharma Corporation, a clinical stage pharmaceutical company, develops a proprietary intracutaneous delivery system to administer drugs through the skin for rapid symptom relief to patients.The company has $48.61 million market cap. The Company’s lead product candidate is M207, a proprietary formulation of zolmitriptan used for the treatment of migraine.Currently it has negative earnings.

For more Zosano Pharma Corporation (NASDAQ:ZSAN) news released briefly go to: Benzinga.com, Streetinsider.com, Benzinga.com, Streetinsider.com or Benzinga.com. The titles are as follows: “40 Stocks Moving In Thursday’s Mid-Day Session” released on June 28, 2018, “After-Hours Stock Movers 06/27: (EDGE) (ZSAN) (MSG) Higher; (PIR) (BBBY) (XON) Lower (more…)” on June 27, 2018, “20 Stocks Moving In Thursday’s Pre-Market Session” with a publish date: June 28, 2018, “Zosano Pharma (ZSAN) Announces Publication of Study on ADAM Technology for Delivery of Zolmitriptan” and the last “48 Biggest Movers From Yesterday” with publication date: June 29, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: